trending Market Intelligence /marketintelligence/en/news-insights/trending/6jd405fs1727rla-88zv7a2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Insmed files application with US FDA for lung disease therapy


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Insmed files application with US FDA for lung disease therapy

Insmed Inc. a submitted a new drug application to the U.S. Food and Drug Administration for its lung disease treatment amikacin liposome inhalation suspension, or ALIS.

ALIS is aimed at treating adult patients with nontuberculous mycobacterial lung disease, a rare infection that can damage the lungs. The disease is caused by mycobacterium avium complex, a type of bacteria that affects people whose immune system is weak.

The application for the inhaled, once-daily formulation, is based on a successful phase 3 study, in which adding ALIS to standard treatment reduced bacterial density in 29% of the 336 adult patients enrolled.

Insmed expects to receive a six-month priority review from the U.S. FDA for ALIS.